Rosa Lapalombella

4.2k total citations
85 papers, 1.9k citations indexed

About

Rosa Lapalombella is a scholar working on Molecular Biology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Rosa Lapalombella has authored 85 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Molecular Biology, 46 papers in Genetics and 20 papers in Pathology and Forensic Medicine. Recurrent topics in Rosa Lapalombella's work include Chronic Lymphocytic Leukemia Research (42 papers), Lymphoma Diagnosis and Treatment (17 papers) and Monoclonal and Polyclonal Antibodies Research (14 papers). Rosa Lapalombella is often cited by papers focused on Chronic Lymphocytic Leukemia Research (42 papers), Lymphoma Diagnosis and Treatment (17 papers) and Monoclonal and Polyclonal Antibodies Research (14 papers). Rosa Lapalombella collaborates with scholars based in United States, Italy and Poland. Rosa Lapalombella's co-authors include John C. Byrd, Natarajan Muthusamy, Amy J. Johnson, Amy Lehman, Lapo Alinari, Leslie A. Andritsos, Robert A. Baiocchi, David Jarjoura, Marina Marini and Lisa L. Smith and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

Rosa Lapalombella

79 papers receiving 1.8k citations

Peers

Countries citing papers authored by Rosa Lapalombella

Since Specialization

Citations

This map shows the geographic impact of Rosa Lapalombella's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rosa Lapalombella with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rosa Lapalombella more than expected).

Fields of papers citing papers by Rosa Lapalombella

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rosa Lapalombella. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rosa Lapalombella. The network helps show where Rosa Lapalombella may publish in the future.

Co-authorship network of co-authors of Rosa Lapalombella

This figure shows the co-authorship network connecting the top 25 collaborators of Rosa Lapalombella. A scholar is included among the top collaborators of Rosa Lapalombella based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rosa Lapalombella. Rosa Lapalombella is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	SINE compounds activate exportin 1 degradation through an allosteric mechanism 2025 ·Nature Chemical Biology ·(unknown), Ho Yee Joyce Fung, (unknown), Tolga Çağatay, (unknown), Maarten Jacquemyn, (unknown), (unknown), (unknown), (unknown), Joseph M. Ready, Trinayan Kashyap, Sharon Shacham, Yosef Landesman, Rosa Lapalombella, Dirk Daelemans, Yuh Min Chook	0
2	Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study 2022 ·Clinical Cancer Research ·Deborah M. Stephens, Ying Huang, Amy S. Ruppert, (unknown), (unknown), (unknown), Qiang Fu, Sharyn D. Baker, Boyu Hu, Harsh Shah, (unknown), Kerry A. Rogers, Seema A. Bhat, Samantha Jaglowski, Hank Lockman, Rosa Lapalombella, John C. Byrd, Jennifer A. Woyach	20
3	HDAC1 regulates the chromatin landscape to control transcriptional dependencies in chronic lymphocytic leukemia 2022 ·Blood Advances ·(unknown), Hatice Gülçin Özer, Pierluigi Gasparini, Giovanni Nigita, Rosario Distefano, (unknown), (unknown), (unknown), Juan Gallegos, Sachet A. Shukla, Vinay K. Puduvalli, Jennifer A. Woyach, Rosa Lapalombella, James S. Blachly, John C. Byrd, Deepa Sampath	7
4	Hedgehog-induced PD-L1 on tumor-associated macrophages is critical for suppression of tumor-infiltrating CD8+ T cell function 2021 ·JCI Insight ·Amy J. Petty, Rui Dai, Rosa Lapalombella, Robert A. Baiocchi, Don M. Benson, Zihai Li, Xiaopei Huang, Yiping Yang	79
5	Significance of chromosome 2p gain in ibrutinib-treated chronic lymphocytic leukemia patients 2021 ·Leukemia ·Cecelia Miller, Ying Huang, Amy S. Ruppert, (unknown), Samantha Jaglowski, Kami J. Maddocks, Kerry A. Rogers, Seema A. Bhat, Adam S. Kittai, Michael R. Grever, Rosa Lapalombella, Lynne V. Abruzzo, Nyla A. Heerema, John C. Byrd, Erin Hertlein, Jennifer A. Woyach	0
6	Large-Scale Drug Screen Identifies FDA-Approved Drugs for Repurposing in Sickle-Cell Disease 2020 ·Journal of Clinical Medicine ·Matthew Cannon, Hannah Phillips, (unknown), Katie Williams, Lindsey T. Brinton, Charles T. Gregory, (unknown), Payal Desai, (unknown), Rosa Lapalombella	4
7	TP-0903 is active in models of drug-resistant acute myeloid leukemia 2020 ·JCI Insight ·(unknown), Daelynn R. Buelow, (unknown), Mingshan Niu, Eric D. Eisenmann, Kevin M. Huang, (unknown), (unknown), Clifford J. Whatcott, (unknown), Shelley Orwick, (unknown), (unknown), Lindsey T. Brinton, Rosa Lapalombella, James S. Blachly, Erin Hertlein, John C. Byrd, Bhavana Bhatnagar, Sharyn D. Baker	21
8	Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia 2020 ·Journal of Hematology & Oncology ·Lindsey T. Brinton, Pu Zhang, Katie Williams, (unknown), Shelley Orwick, (unknown), (unknown), Larry Beaver, (unknown), (unknown), Matthew Cannon, (unknown), Bonnie K. Harrington, Amy Lehman, John C. Byrd, Rosa Lapalombella, James S. Blachly	37
9	Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia 2020 ·Journal of Hematology & Oncology ·Ola A. Elgamal, (unknown), (unknown), (unknown), Amy Lehman, Shelley Orwick, (unknown), Virginia M. Goettl, (unknown), (unknown), Shaneice Mitchell, Rosa Lapalombella, Sudharshan Eathiraj, Brian Schwartz, Kimberly Stegmaier, Sharyn D. Baker, Erin Hertlein, John C. Byrd	14
10	Eμ-TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma 2019 ·Clinical Cancer Research ·Fabienne Lucas, Kerry A. Rogers, Bonnie K. Harrington, (unknown), Lianbo Yu, (unknown), Ralf Bundschuh, Virginia M. Goettl, Zachary A. Hing, (unknown), Rose Mantel, Deepa Sampath, Lisa L. Smith, (unknown), (unknown), Pearlly S. Yan, John C. Byrd, Rosa Lapalombella, Jennifer A. Woyach	18
11	Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia 2015 ·Blood ·Zachary A. Hing, Rose Mantel, Kyle A. Beckwith, Daphne Guinn, (unknown), Lisa L. Smith, Katie Williams, Amy J. Johnson, Amy M. Lehman, John C. Byrd, Jennifer A. Woyach, Rosa Lapalombella	72
12	The Proteasome Inhibitor Carfilzomib Functions Independently of p53 to Induce Cytotoxicity and an Atypical NF-κB Response in Chronic Lymphocytic Leukemia Cells 2013 ·Clinical Cancer Research ·Sneha Gupta, Erin Hertlein, Yanhui Lu, Ellen J. Sass, Rosa Lapalombella, Timothy L. Chen, Melanie E. Davis, Jennifer A. Woyach, Amy Lehman, David Jarjoura, John C. Byrd, David Lucas	31
13	Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia 2010 ·Leukemia & lymphoma ·Farrukh T. Awan, Amy J. Johnson, Rosa Lapalombella, Weihong Hu, Margaret S. Lucas, Beth Fischer, John C. Byrd	23
14	The humanized CD40 antibody SGN‐40 demonstrates pre‐clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia 2009 ·British Journal of Haematology ·Rosa Lapalombella, Aruna Gowda, Trupti Joshi, (unknown), Carolyn Cheney, Amy Lehman, Ching‐Shih Chen, Amy J. Johnson, Michael A. Caligiuri, Susheela Tridandapani, Natarajan Muthusamy, John C. Byrd	32
15	Higher Doses of Lenalidomide Are Associated With Unacceptable Toxicity Including Life-Threatening Tumor Flare in Patients With Chronic Lymphocytic Leukemia 2008 ·Journal of Clinical Oncology ·Leslie A. Andritsos, Amy J. Johnson, Gerard Lozanski, William Blum, Cheryl Kefauver, Farrukh T. Awan, Lisa L. Smith, Rosa Lapalombella, Sarah May, Chelsey A. Raymond, Da-Sheng Wang, Robert Knight, Amy S. Ruppert, Amy Lehman, David Jarjoura, Ching-Shih Chen, John C. Byrd	117
16	Persistence of regenerative myogenesis in spite of down-regulation of activity-dependent genes in long-term denervated rat muscle 2008 ·Neurological Research ·Rosa Lapalombella, Helmut Kern, Nicoletta Adami, Donatella Biral, Sandra Zampieri, (unknown), (unknown), Marina Marini	21
17	Modulation of paraoxonase 1 and 3 expression after moderate exercise training in the rat 2008 ·Journal of Lipid Research ·Rita Romani, Gianna Evelina De Medio, (unknown), Rosa Lapalombella, (unknown), V. Margonato, A. Veicsteinas, Marina Marini, Gabriella Rosi	30
18	Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia 2007 ·Oncogene ·Lapo Alinari, Rosa Lapalombella, Leslie A. Andritsos, Robert A. Baiocchi, Thomas S. Lin, John C. Byrd	84
19	Mild exercise training, cardioprotection and stress genes profile 2007 ·European Journal of Applied Physiology ·Marina Marini, Rosa Lapalombella, V. Margonato, Raffaella Ronchi, Michele Samaja, Cristina Scapin, Luisa Gorza, Tullia Maraldi, Paolo Carinci, Carlo Ventura, A. Veicsteinas	58
20	Sequential events of apoptosis involving docetaxel, a microtubule-interfering agent: A cytometric study 2006 ·BMC Cell Biology ·Francesco� Fabbri, Silvia Carloni, Giovanni Brigliadori, Wainer Zoli, Rosa Lapalombella, Marina Marini	63

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact